Activity measurements and determination of nuclear decay data of 166Ho in the MRTDosimetry project

Holmium-166 is a high-energy β−-emitter radionuclide (~ 1.8 MeV) with a short half-life (~26.8h) that offers great potential as an alternative to 90Y for the treatment of liver cancer based on radioembolization. The possibility of quantitative Single Photon Emission Computed Tomography (SPECT) imagi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Applied radiation and isotopes 2019-11, Vol.153, p.108826-108826, Article 108826
Hauptverfasser: Bobin, C., Bouchard, J., Chisté, V., Collins, S.M., Dryák, P., Fenwick, A., Keightley, J., Lépy, M.-C., Lourenço, V., Robinson, A.P., Sochorová, J., Šolc, J., Thiam, C.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Holmium-166 is a high-energy β−-emitter radionuclide (~ 1.8 MeV) with a short half-life (~26.8h) that offers great potential as an alternative to 90Y for the treatment of liver cancer based on radioembolization. The possibility of quantitative Single Photon Emission Computed Tomography (SPECT) imaging of the main γ-ray emission at 80.6 keV, in addition to strong paramagnetic properties suitable for Magnetic Resonance Imaging (MRI), complement this therapeutic potential. The present paper describes the measurements carried out in three European radionuclide metrology laboratories for primary standardization of 166Ho and new determinations of X- and γ-ray photon-emission intensities in the framework of the European EMPIR project MRTDosimetry. New half-life measurements were also performed. •Standardization of 166Ho performed using three primary techniques at three NMIs.•Absolute X- and γ-ray intensities determined by γ-ray spectrometry.•Five half-life measurements performed by ionization chamber and gamma-ray spectrometry.
ISSN:0969-8043
1872-9800
DOI:10.1016/j.apradiso.2019.108826